Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Intelligent Bio Solutions ( (INBS) ) is now available.
On January 7, 2026, Intelligent Bio Solutions Inc. announced that it had regained compliance with Nasdaq’s minimum bid price requirement after previously falling out of compliance when its common stock traded below $1.00 per share for 30 consecutive business days leading up to a deficiency notice dated December 16, 2025. The company’s return to compliance, achieved by maintaining a closing bid price of at least $1.00 for 14 consecutive business days from December 16, 2025, to January 6, 2026, removes the immediate risk of delisting from the Nasdaq Capital Market and closes the matter with the exchange’s listing qualifications staff.
The most recent analyst rating on (INBS) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on Intelligent Bio Solutions stock, see the INBS Stock Forecast page.
Spark’s Take on INBS Stock
According to Spark, TipRanks’ AI Analyst, INBS is a Neutral.
The score is held down primarily by weak financial performance—large operating losses and substantial ongoing cash burn—despite improving revenue and a low-debt balance sheet. Technicals are supportive with improved momentum and the stock trading above key moving averages, while valuation remains constrained by negative earnings and no dividend. Corporate developments are mixed, with financing and expected manufacturing cost savings offset by the listing-compliance-driven reverse split.
To see Spark’s full report on INBS stock, click here.
More about Intelligent Bio Solutions
Average Trading Volume: 2,190,496
Technical Sentiment Signal: Sell
Current Market Cap: $10.27M
Find detailed analytics on INBS stock on TipRanks’ Stock Analysis page.